Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 31 March 2023, including: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "The 10 US Biosimilar Launches That Could Drive Big Savings By 2027" - Scrip, 24 Mar, 2023.)
(Also see "Novartis’s Kisqali Strikes Gold In Adjuvant Early Breast Cancer Setting" - Scrip, 27 Mar, 2023.)
(Also see "Novartis’s ‘Poster Child’ Zolgensma Shows What Gene Therapy Can Do – And Its Limitations" - Scrip, 24 Mar, 2023.)
(Also see "Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads" - Scrip, 27 Mar, 2023.)
(Also see "Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion" - Scrip, 29 Mar, 2023.)